Analyst Price Target is $3.00
▲ +506.06% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Palatin Technologies in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 506.06% upside from the last price of $0.50.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Palatin Technologies. This Buy consensus rating has held steady for over two years.
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.